330 related articles for article (PubMed ID: 29393296)
1. Tamoxifen enhances stemness and promotes metastasis of ERα36
Wang Q; Jiang J; Ying G; Xie XQ; Zhang X; Xu W; Zhang X; Song E; Bu H; Ping YF; Yao XH; Wang B; Xu S; Yan ZX; Tai Y; Hu B; Qi X; Wang YX; He ZC; Wang Y; Wang JM; Cui YH; Chen F; Meng K; Wang Z; Bian XW
Cell Res; 2018 Mar; 28(3):336-358. PubMed ID: 29393296
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine kinase 1 activation by estrogen receptor α36 contributes to tamoxifen resistance in breast cancer.
Maczis MA; Maceyka M; Waters MR; Newton J; Singh M; Rigsby MF; Turner TH; Alzubi MA; Harrell JC; Milstien S; Spiegel S
J Lipid Res; 2018 Dec; 59(12):2297-2307. PubMed ID: 30315000
[TBL] [Abstract][Full Text] [Related]
3. From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression.
Chamard-Jovenin C; Jung AC; Chesnel A; Abecassis J; Flament S; Ledrappier S; Macabre C; Boukhobza T; Dumond H
BMC Syst Biol; 2015 Jun; 9():28. PubMed ID: 26080803
[TBL] [Abstract][Full Text] [Related]
4. 14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer.
Garan LAW; Xiao Y; Lin WC
Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2209211119. PubMed ID: 36252018
[TBL] [Abstract][Full Text] [Related]
5. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
6. SpliceArray profiling of breast cancer reveals a novel variant of NCOR2/SMRT that is associated with tamoxifen resistance and control of ERα transcriptional activity.
Zhang L; Gong C; Lau SL; Yang N; Wong OG; Cheung AN; Tsang JW; Chan KY; Khoo US
Cancer Res; 2013 Jan; 73(1):246-55. PubMed ID: 23117886
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
8. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
9. The Role of ERα36 in Development and Tumor Malignancy.
Thiebaut C; Konan HP; Guerquin MJ; Chesnel A; Livera G; Le Romancer M; Dumond H
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32526980
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into tumor-specific chaperoning activity of gamma synuclein in protecting estrogen receptor alpha 36 and its role in tamoxifen resistance in breast cancer.
Panneerselvam M; Muthu K; Ramadas K
Mol Biosyst; 2015 Nov; 11(11):2998-3010. PubMed ID: 26299756
[TBL] [Abstract][Full Text] [Related]
11. Expression and localization of estrogen receptor in human breast cancer and its clinical significance.
Li L; Wang Q; Lv X; Sha L; Qin H; Wang L; Li L
Cell Biochem Biophys; 2015 Jan; 71(1):63-8. PubMed ID: 25113640
[TBL] [Abstract][Full Text] [Related]
12. Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required.
Mansouri S; Farahmand L; Teymourzadeh A; Majidzadeh-A K
Curr Cancer Drug Targets; 2018; 18(7):668-676. PubMed ID: 28786348
[TBL] [Abstract][Full Text] [Related]
13. The fight against tamoxifen resistance in breast cancer therapy: a new target in the battle?
Nichols M
Mol Interv; 2007 Feb; 7(1):13-6. PubMed ID: 17339602
[TBL] [Abstract][Full Text] [Related]
14. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
15. Adherence to long-term adjuvant hormonal therapy for breast cancer.
Gotay C; Dunn J
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
Bostner J; Skoog L; Fornander T; Nordenskjöld B; Stål O
Clin Cancer Res; 2010 Mar; 16(5):1624-33. PubMed ID: 20179234
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant endocrine treatment of early breast cancer.
Lønning PE
Hematol Oncol Clin North Am; 2007 Apr; 21(2):223-38. PubMed ID: 17512446
[TBL] [Abstract][Full Text] [Related]
18. Advances in adjuvant hormonal therapy for postmenopausal women.
Strasser-Weippl K; Goss PE
J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
[No Abstract] [Full Text] [Related]
19. [Advancement in endocrine therapy for breast cancer].
Yang MT; Lian ZQ
Ai Zheng; 2007 Apr; 26(4):440-4. PubMed ID: 17430670
[TBL] [Abstract][Full Text] [Related]
20. ERα36-GPER1 Collaboration Inhibits TLR4/NFκB-Induced Pro-Inflammatory Activity in Breast Cancer Cells.
Notas G; Panagiotopoulos A; Vamvoukaki R; Kalyvianaki K; Kiagiadaki F; Deli A; Kampa M; Castanas E
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
